c 7

(S,R,S)-AHPC-Me-C7 ester is an E3 ligase ligand-linker conjugate used to synthesize BCL-XL PROTAC degraders[1].

Thalidomide-O-C7-NH2 is a synthesized conjugate compound comprising an E3 ligase ligand-linker conjugate. This compound incorporates a cereblon ligand based on Thalidomide and a linker that is commonly employed in PROTAC technology.

Thalidomide-O-C7-acid is a compound synthesized as an E3 ligase ligand-linker conjugate, consisting of a cereblon ligand derived from Thalidomide and a linker commonly used in PROTAC technology.

Pomalidomide-C7-COOH is a chemically synthesized E3 ligase cereblon ligand-linker conjugate, utilized as an intermediate compound for the synthesis of PROTAC BCL-XL degraders.

(S,R,S)-AHPC-C7-amine, also known as VH032-C7-amine, is a chemically synthesized conjugate that serves as an E3 ligase ligand-linker, combining the VH032-based VHL ligand with a specific linker for the degradation of estrogen-related receptor α (ERRα) PROTAC.

Pomalidomide-C7-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based CRBN ligand and linker used in PROTAC technology.

Quin-C7 is an orally active FPR2/ALX antagonist with anti-inflammatory properties. It demonstrates efficacy in ameliorating DSS-induced colitis in mice and is suitable for research in inflammatory bowel disease [IBD].

(S,R,S)-AHPC-C7-amine (VH032-C7-amine) hydrochloride is a synthetic E3 ligase ligand-linker conjugate, incorporating a VH032-based VHL ligand and a linker. This compound is utilized in the synthesis of PROTAC degraders targeting ERRα.

Pomalidomide-5-C7-NH2 hydrochloride is a ligand for the E3 ubiquitin ligase cereblon (CRBN) based on Pomalidomide. It is used to recruit cereblon protein and can be linked via a linker to a protein ligand to form a PROTAC.

(S,R,S)-AHPC-C7-aminedihydrochloride is the dihydrochloride salt form of (S,R,S)-AHPC-C7-amine. The compound (S,R,S)-AHPC-C7-amine is a synthetic E3 ligase ligand-linker (E3ligaseligand-linker conjugate) that includes a VHL ligand based on VH032 and one linker. It is utilized for synthesizing PROTAC degraders targeting ERRα.

Pomalidomide-CO-C7-NH-CO-C3-COOH is a conjugated compound that acts as both an E3 ligase ligand and a linker, and it is employed in synthesizing the PROTAC degrader ARM165.

COOH-C3-COGN-C7-COOH is a PEG-type PROTAC linker utilized for synthesizing PROTAC Degrader ARM165.

Thalidomide-N-C-piperidine-C7-Br, an E3 ligase ligand-linker conjugate (E3 ligase Ligand-linker conjugate), consists of a cereblon (CRBN) ligand for the E3 ubiquitin ligase and a linker. Thalidomide-N-C-piperidine-C7-Br is utilized in the synthesis of ZS3-046.

T-01-C7-amide is an E3 ligase ligand-linker conjugate (E3 ligase Ligand-linker conjugate) employed in the synthesis of PROTAC BRD4 Degrader-36.

5-Aminothalidomide-NH-C7-NH2 is an E3 ubiquitin ligase ligand-linker conjugate (E3 ligase Ligand-linker conjugate) that incorporates a CRBN ligand based on 5-Aminothalidomide and a linker. It is utilized in the synthesis of PROTACBT-O2C.

Thalidomide-4-O-C7-NH2 hydrochloride, a Thalidomide-based cereblon ligand, plays a role in the recruitment of CRBN protein and, when linked to a protein ligand, forms PROTACs [1].

Thalidomide-5-O-C7-NH2 hydrochloride, a Thalidomide-based cereblon ligand, facilitates CRBN protein recruitment. This compound can be tethered to a protein-targeting ligand using a linker, enabling the formation of PROTACs [1].

AP-C7 is a selective inhibitor of cGMP-dependent protein kinase II (cGKII) with a pIC50 value of 5.0, demonstrating only weak inhibition of cGKII-dependent anion secretion [1].

FRα-targeting peptide C7 TFA is a selective peptide ligand for the folate receptor alpha (FRα) that specifically binds to FRα-expressing cells and has tumor-targeting capabilities in vivo. It is applicable in research related to tumor diagnosis and therapy.

3'-Amino-Modifier C7 CPG 1000 is a reagent used in biochemical reactions.

C7:0-CoA (C7:0-Coenzyme A) is a derivative of coenzyme A.

Cdc7-IN-7c (Cdc7 inhibitor-7c) has antitumor activity and has inhibitory effect on liver cancer, lung cancer, kidney cancer, brain cancer and cervical cancer.

Triheptanoin (IND 106011) is a fatty acid metabolic modulator. It potentially for the treatment of fatty acid oxidation disorders and GLUT1.

VH 032 amide-alkylC7-acid is a specialized compound designed for PROTAC research and development, serving as a functionalized von-Hippel-Lindau (VHL) protein ligand. It combines an E3 ligase ligand with an alkylC7 linker, ending in a terminal carboxylic acid for efficient conjugation to target protein ligands. This compound is among a series of functionalized tool molecules aimed at facilitating PROTAC R&D efforts.